Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI

Not yet recruiting

• Conditions: Esophageal Cancer; Neoadjuvant Therapy

• Registration Number: NCT06833775
• Lead Sponsor: Henan Cancer Hospital

Brief Summary

This study aims to predict the efficacy of different types of neoadjuvant therapy and related postoperative pathological indicators in patients with esophageal cancer based on imaging parameters from CT and multimodal MRI, as well as clinical indicators collected before and after neoadjuvant treatment.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-02
• Study First Submitted: 2025-02-13
• Study First Submitted QC: 2025-02-13
• Last Update Submitted: 2025-02-18
• Study First Posted: 2025-02-19
• Last Update Posted: 2025-02-20
• Study Start: 2025-03
• Primary Completion: 2030-01
• Study Completion: 2030-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

1. Consecutive patients with histopathological diagnosis of esophageal cancer.
2. Patients underwent neoadjuvant therapy before radical surgery for esophageal cancer: neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, neoadjuvant chemotherapy plus immunotherapy, neoadjuvant chemoradiotherapy plus immunotherapy.
3. All patients underwent CT and multimodal MRI examinations before and after neoadjuvant therapy.
4. The preoperative clinical data and postoperative pathological data are complete.

Exclusion Criteria

1. Patients with other primary malignant tumors or previous anti-tumor treatment.
2. CT and MRI images with poor quality.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CT and multimodal MRI in prediction of neoadjuvant therapy efficacy and postoperative pathological indicators in esophageal cancer	March 2025 - January 2030	To evaluate the effectiveness of CT and multimodal MRI in determining the neoadjuvant therapy efficacy and postoperative pathological indicators in esophageal cancer.